Peter Mclaughlin

Biography

Prior to joining the MD Anderson Physicians Network® in 2010, McLaughlin had been Professor of Medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center. McLaughlin received his undergraduate degree from Harvard University College, and his M.D. from Tufts University School of Medicine. McLaughlin's research focus was on the integration of new therapies, particularly biological therapies, for the management of patients with indolent lymphoma. He has authored and co-authored over 200 journal articles and book chapters. He was the lead investigator of the multicenter pivotal trial of rituximab that led to its approval by the FDA in 1997. His collaborative activities ranged from inter-departmental projects at MDACC to international ones such as the development of the Follicular Lymphoma International Prognostic Index (FLIPI). In addition to his patient care and clinical research roles, McLaughlin also participated in departmental and institutional initiatives related to medical records (including MD Anderson's transition to an electronic medical record), database development and maintenance, and quality improvement.

Research Interest

Cancer